Overview

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

Status:
Recruiting

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

This trial will try to establish the feasibility and efficacy of the combination of DaraVCD in Multiple Myeloma (MM) patients presenting with extramedullary disease (EMD). The study will be conducted as a Phase II trial. Forty patients will be included in the study cohort. All patients will be followed closely for toxicities and response assessment. After completion of treatment, patients will be followed every 6 months for survival until 5 years after enrolment

Phase:

Phase 2

Details

Lead Sponsor:

European Myeloma Network

Collaborator:

Janssen, LP

Treatments:

Antibodies, Monoclonal
BB 1101
Bortezomib
Cyclophosphamide
Daratumumab
Dexamethasone
Dexamethasone acetate